Daiichi Sankyo Co., Ltd. (TSE:4568) shares surged 6.2% after the pharmaceutical company announced robust fourth-quarter earnings that surpassed expectations, coupled with a significant share buyback ...

On March 28, the FDA approved Imfinzi for use in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent Imfinzi as adjuvant treatment after radical cystectomy, ...

EAGLE-1 trial data shows gepotidacin’s potential in treating gonorrhoea, for which no new antibiotics have been approved ...

The DXd ADC portfolio currently consists of ENHERTU, a HER2 directed ADC, and DATROWAY, a TROP2 directed ADC, which are being jointly developed and commercialized globally with AstraZeneca.

Astra said a trial of its Enhertu treatment showed the drug demonstrated a 'highly statistically significant' improvement on ...

Drugmaker AstraZeneca said on Tuesday that it had received "positive high-level results" from a Phase III trial on its ...

Condor Partners and Northlight Capital Partners, with JP Partners brokering the deal, are pleased to announce new funding for Mural Park, a 200,000-square-foot, Class A office project in Chicago, ...

Springtime in Washington, D.C., is synonymous with cherry blossom season, when the thousands of cherry blossom trees gifted ...

This week, the European Commission granted marketing authorization to the expanded use of AbbVie’s ABBV Rinvoq and AstraZeneca’s AZN blockbuster cancer drugs, Imfinzi and Daiichi-Sankyo partnered, ...

When I told my friend my next nasi lemak stop was 100 Years Nasi Lemak at Jalan Galloway in Bukit Bintang, she quipped, “You’re gonna wait 100 years for a plate of nasi lemak? Bit much, even for you.” ...

Chinese biotech RemeGen (SHA: 688331) has reported positive late-stage clinical trial data for its dual-target fusion protein telitacicept in patients with generalized myasthenia gravis, offering a ...